Discover and read the best of Twitter Threads about #cabozantinib

Most recents (3)

1/ #OncTwitter #NephTwitter #TumorBoardTuesday
#RenalCell #MedTweetorial🧵
w @brian_rini @shilpaonc @katy_beckermann

🦺TKI/IO safety data
🥽Tox to look 4
⛑AE mgmt

🆓#CME @BonumCe🔗bit.ly/3VDaK81
Support by edu grants from Eisai & @Merck

🟢What's your specialty?
2/ #TumorBoardTuesday #BonumCE #RenalCell #OncTwitter #NephTwitter
🆓#CME info ➕ full ref list🗒️ 👉 bit.ly/3VDaK81

✳️The critical elements👇 Image
3/ #TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter

🟢 Which of the following TKI/IO combo regimens is 🚫NOT approved by the FDA for the frontline mgmt of #RenalCell carcinoma?
Read 27 tweets
So I realized it might be good to do a recap here of my story, otherwise known as, “No, really, I promise I almost died six years ago.”

(I guess this is probably a good time to warn you all that I have a warped sense of humor. #thankscancer )
May 2016, five days after my 29th birthday, I am diagnosed in an @StRoseHospitals ER when a CT scan finds a 13 cm tumor that has taken over my right kidney. The amazing ER doctor & PA had already called a local urologist so I can see him first thing in the morning.
My local (Vegas) urologist says, “I’ve got one surgeon in town who *might* be willing to take your case.” Yikes! He encourages going to CA instead, specifically to @UCLAHealth. He steps out of the room & calls the surgeon who did *his* nephrectomy on his cell phone to get me in.
Read 24 tweets
@myESMO #ESMO20 as a #trainee can be #overwhelming! So many good studies, some more #practicechanging then others, if you missed some and want to understand (albeit at a simplistic #trainee level), sit back, relax and enjoy as we go through some great data #ESMO20 @OncoAlert
1. #NSCLC: 2 major studies #ADAURA #CROWN for adjuvant #EGFRmNSCLC, and advanced #ALK+ experts can provide better perspective @JackWestMD @n8pennell @StephenVLiu @AMansfieldMD @CharuAggarwalMD @NarjustDumaMD @GlopesMd @DevikaDasMD @OncoAlert
1. A) #ADAURA: Stage IB-IIIA #resected #NSCLC with #EGFRm treated with #Osimertinib vs #placebo [SOC prior to this was adjuvant chemotherapy [cisplatin-based doublet based on #LACE metanalysis- pubmed.ncbi.nlm.nih.gov/18506026/] showed improvement in #DFS @NEJM nejm.org/doi/full/10.10…
Read 19 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!